The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 329:665-666 August 26, 1993 Number 9
NextNext

Growth Hormone, Insulin-like Growth Factor I, and Benign Intracranial Hypertension

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: The Food and Drug Administration, after receiving 6 reports of benign intracranial hypertension (pseudotumor cerebri) in patients treated with recombinant growth hormone, actively identified an additional 17 affected patients in the United States or abroad. Benign intracranial hypertension was also reported in three patients with resistance to growth hormone who were treated with insulin-like growth factor I, the primary mediator of the actions of growth hormone.

The 23 cases -- 22 in children and 1 in an adult -- associated with growth hormone treatment occurred between 1986 and 1993. Among the children, seven had growth hormone deficiency, . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.